Abstract
A growing body of evidence indicates that self-measurement of blood glucose (SMBG) also has beneficial effects in people with type 2 diabetes, irrespective of the type of therapy. The objective of this analysis was to determine the economic impact of SMBG by comparing the cost share of self-monitoring and the direct costs of diabetes-related complications in users and non-users. A matched-pair analysis based on the cohorts of a large retrospective study of patients with type 2 diabetes (ROSSO) was conducted. The average annual direct costs of diabetes monitoring, treatment-related services, complications and follow-up costs of the disease for SMBG users versus non-users were calculated from the perspective of the Czech statutory health insurance system. Univariate sensitivity analysis was performed to determine the main cost drivers. Limitations of this study are: (1) differences in medical facilities/practice between Germany and the Czech Republic, (2) causal relationship between SMBG and health outcomes is missing, (3) ROSSO underestimated the number of test strips used, (4) Czech cost data are scarce. In patients treated with oral antidiabetic drugs (OAD) only, total annual costs in Czech koruna (CZK) were CZK 16 476 for SMB...Continue Reading
References
Sep 24, 1983·British Medical Journal·J H FullerH Keen
Jun 15, 1994·JAMA : the Journal of the American Medical Association·T A MassaroI Kalman
Feb 1, 1993·Diabetes Care·J StamlerD Wentworth
Sep 11, 1998·BMJ : British Medical Journal
Dec 29, 2000·Diabetes Care·T S Temelkova-KurktschievM Hanefeld
Jul 13, 2001·The American Journal of Medicine·A J KarterJ V Selby
Mar 26, 2003·Diabetologia·A Ceriello
Sep 30, 2003·Diabetes Care·Rachel DerrChristopher D Saudek
Apr 2, 2005·Current Medical Research and Opinion·Jesus N SarolMaritess B Grava
Jun 25, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·M FranciosiUNKNOWN QuED Study Group--Quality of Care and Outcomes in Type 2 Diabetes
Oct 18, 2005·The American Journal of Medicine·Lawrence Blonde, Andrew J Karter
Dec 20, 2005·Diabetologia·S MartinW A Scherbaum
May 11, 2006·Current Medical Research and Opinion·Jeroen P Jansen
Jul 29, 2006·Diabetes Care·Andrew J KarterJoe V Selby
Jul 29, 2006·Diabetes Care·Wendy A DavisTimothy M E Davis
Jan 24, 2007·Diabetologia·W A DavisT M E Davis
Jun 1, 2007·Diabetes/metabolism Research and Reviews·Grace McGeochR Andrew Moore
Sep 25, 2007·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Josephine A MauskopfPaul Trueman
Feb 16, 2008·Diabetes Technology & Therapeutics·Luigi F Meneghini
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Jan 6, 2009·Diabetes Care·UNKNOWN American Diabetes Association
Feb 1, 2005·Expert Review of Pharmacoeconomics & Outcomes Research·Josephine A MauskopfC Daniel Mullins
Sep 1, 2007·Journal of Diabetes Science and Technology·Oliver Schnell, Lutz Heinemann
Jan 1, 2008·Journal of Diabetes Science and Technology· Hubert Kolb Stephan Martin
Citations
Jun 28, 2012·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Jason YeawDanielle Groleau
Nov 22, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Carlo B GiordaJesús Diago Cabezudo
Aug 12, 2016·Journal of Diabetes Science and Technology·Kurt FortwaenglerOliver Mast
Apr 30, 2014·Journal of Medical Economics·Victoria K BrennanRoberto Palencia